Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Payables (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Payables for 16 consecutive years, with $32.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 127.83% year-over-year to $32.9 million, compared with a TTM value of $32.9 million through Dec 2025, up 127.83%, and an annual FY2025 reading of $17.7 million, up 55.2% over the prior year.
  • Payables was $32.9 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $17.7 million in the prior quarter.
  • Across five years, Payables topped out at $35.9 million in Q3 2023 and bottomed at $796000.0 in Q4 2022.
  • Average Payables over 5 years is $13.1 million, with a median of $9.8 million recorded in 2023.
  • The sharpest move saw Payables tumbled 80.43% in 2022, then surged 1150.56% in 2023.
  • Year by year, Payables stood at $4.1 million in 2021, then crashed by 80.43% to $796000.0 in 2022, then surged by 460.3% to $4.5 million in 2023, then surged by 224.15% to $14.5 million in 2024, then surged by 127.83% to $32.9 million in 2025.
  • Business Quant data shows Payables for ARWR at $32.9 million in Q4 2025, $17.7 million in Q3 2025, and $33.0 million in Q2 2025.